Market Opportunity Target a high-value addressable market for acute heart failure devices, with potential upside up to $10 billion, indicating opportunities to engage major healthcare providers, hospitals, and reimbursement stakeholders.

Strategic Partnerships Leverage the JLABS @ TMC affiliation and Wellcome Trust lead investment to approach academic medical centers, research hospitals, and translational partners for pilot deployments, clinical validation, and co-development.

Non-blood Contact Focus sales messaging around the device’s non-blood contacting, minimally invasive, soft robotic advantages to address safety, reduce adverse events, and broaden patient eligibility compared with traditional devices.

Clinical Advantage Highlight potential to increase cardiac output by up to 50% and the possibility of reversing or halting heart failure progression, guiding conversations with cardiology departments and heart failure programs.

Funding & Growth Position CorInnova as an early-stage, well-backed innovator with $7.3M in funding and revenue in the low-to-mid seven figures, suitable for investment discussions, grant opportunities, and collaboration with device manufacturers seeking disruptive tech.